Skip Navigation
Skip to contents

Intest Res : Intestinal Research

IMPACT FACTOR

Author index

Page Path
HOME > Browse articles > Author index
Search
Shin Fujioka 1 Article
IBD
One-year clinical efficacy and safety of indigo naturalis for active ulcerative colitis: a real-world prospective study
Yuichi Matsuno, Takehiro Torisu, Junji Umeno, Hiroki Shibata, Atsushi Hirano, Yuta Fuyuno, Yasuharu Okamoto, Shin Fujioka, Keisuke Kawasaki, Tomohiko Moriyama, Tomohiro Nagasue, Keizo Zeze, Yoichiro Hirakawa, Shinichiro Kawatoko, Yutaka Koga, Yoshinao Oda, Motohiro Esaki, Takanari Kitazono
Intest Res 2022;20(2):260-268.   Published online April 29, 2022
DOI: https://doi.org/10.5217/ir.2021.00124
AbstractAbstract PDFSupplementary MaterialPubReaderePub
Background/Aims
Recent studies suggested a favorable effect of indigo naturalis (IN) in inducing remission for refractory ulcerative colitis (UC), however, the maintenance effect of IN for patients with UC remains unknown. Therefore, we conducted a prospective uncontrolled open-label study to analyze the efficacy and safety of IN for patients with UC.
Methods
Patients with moderate to severe active UC (clinical activity index [CAI] ≥ 8) took 2 g/day of IN for 52 weeks. CAI at weeks 0, 4, 8, and 52 and Mayo endoscopic subscore (MES) and Geboes score (GS) at weeks 0, 4, and 52 were assessed. Clinical remission (CAI ≤ 4), mucosal healing (MES ≤ 1), and histological healing (GS ≤ 1) rates at each assessment were evaluated. Overall adverse events (AEs) during study period were also evaluated. The impact of IN on mucosal microbial composition was assessed using 16S ribosomal RNA gene sequences.
Results
Thirty-three patients were enrolled. The rates of clinical remission at weeks 4, 8, and 52 were 67%, 76%, and 73%, respectively. The rates of mucosal healing at weeks 4 and 52 were 48% and 70%, respectively. AEs occurred in 17 patients (51.5%) during follow-up. Four patients (12.1%) showed severe AEs, among whom 3 manifested acute colitis. No significant alteration in the mucosal microbial composition was observed with IN treatment.
Conclusions
One-year treatment of moderate to severe UC with IN was effective. IN might be a promising therapeutic option for maintaining remission in UC, although the relatively high rate of AEs should be considered.

Citations

Citations to this article as recorded by  
  • Risk of Infection in Patients With Inflammatory Bowel Disease Treated With Interleukin-Targeting Agents: A Systematic Review and Meta-Analysis
    Konstantinos Ouranos, Hira Saleem, Stephanos Vassilopoulos, Athanasios Vassilopoulos, Evangelia K Mylona, Fadi Shehadeh, Markos Kalligeros, Bincy P Abraham, Eleftherios Mylonakis
    Inflammatory Bowel Diseases.2025; 31(1): 37.     CrossRef
  • Selected Use of Complementary and Alternative Medicine (CAM) Agents in IBD
    Monica Dzwonkowski, Janak Bahirwani, Samantha Rollins, Alicia Muratore, Vikram Christian, Yecheskel Schneider
    Current Gastroenterology Reports.2025;[Epub]     CrossRef
  • Indigo naturalis (Qing dai) for inflammatory bowel disease: A systematic review and meta-analysis
    Rinkalben Kakdiya, Daya Krishna Jha, Arup Choudhury, Anuraag Jena, Vishal Sharma
    Clinics and Research in Hepatology and Gastroenterology.2024; 48(1): 102250.     CrossRef
  • Reply to “Ferroptosis in the colon epithelial cells as a therapeutic target for ulcerative colitis”
    Akihito Yokote, Noriyuki Imazu, Junji Umeno, Keisuke Kawasaki, Shin Fujioka, Yuta Fuyuno, Yuichi Matsuno, Tomohiko Moriyama, Kohta Miyawaki, Koichi Akashi, Takanari Kitazono, Takehiro Torisu
    Journal of Gastroenterology.2024; 59(1): 77.     CrossRef
  • Herbal Medicines for the Treatment of Active Ulcerative Colitis: A Systematic Review and Meta-Analysis
    Preetha Iyengar, Gala Godoy-Brewer, Isha Maniyar, Jacob White, Laura Maas, Alyssa M. Parian, Berkeley Limketkai
    Nutrients.2024; 16(7): 934.     CrossRef
  • Clinical Efficacy and Future Application of Indigo Naturalis in the Treatment of Ulcerative colitis
    Dianzhen Wu, Qi Huang, Yingbi Xu, Ruiyi Cao, Ming Yang, Jin Xie, Dingkun Zhang
    Journal of Ethnopharmacology.2024; : 118782.     CrossRef
  • Ferroptosis in the colon epithelial cells as a therapeutic target for ulcerative colitis
    Akihito Yokote, Noriyuki Imazu, Junji Umeno, Keisuke Kawasaki, Shin Fujioka, Yuta Fuyuno, Yuichi Matsuno, Tomohiko Moriyama, Kohta Miyawaki, Koichi Akashi, Takanari Kitazono, Takehiro Torisu
    Journal of Gastroenterology.2023; 58(9): 868.     CrossRef
  • Hyaluronic acid/inulin-based nanocrystals with an optimized ratio of indigo and indirubin for combined ulcerative colitis therapy via immune and intestinal flora regulation
    Jin Xie, Qi Huang, Huijuan Xie, Jun Liu, Shimin Tian, Ruiyi Cao, Ming Yang, Junzhi Lin, Li Han, Dingkun Zhang
    International Journal of Biological Macromolecules.2023; 252: 126502.     CrossRef
  • High-Quality Indigo Naturalis Obtained with Automatic Foam Separation
    Xin Yang, Jun Tang, Juan Su, Xin Yang, Ming Yang, Xiangbo Yang, Qisen Ji, Yanan He, Li Han, Dingkun Zhang
    ACS Applied Materials & Interfaces.2023; 15(37): 43272.     CrossRef
  • 6,399 View
  • 242 Download
  • 7 Web of Science
  • 9 Crossref
Close layer

Intest Res : Intestinal Research
Close layer
TOP